- The report contains detailed information about Human Genome Sciences Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for Human Genome Sciences Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The Human Genome Sciences Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes Human Genome Sciences Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Human Genome Sciences Inc. business.
About Human Genome Sciences Inc.
Human Genome Sciences, Inc. operates as a biopharmaceutical company. The company also has a pipeline of compounds in earlier stages of clinical development in oncology, immunology and infectious disease. Additional products are in clinical development by companies with which the company is collaborating.
The company has three products in late-stage clinical development: BENLYSTA for systemic lupus, ZALBIN for chronic hepatitis C, and raxibacumab for inhalation anthrax. It also has financial rights to certain products in the GSK clinical pipeline. GlaxoSmithKline (GSK) has advanced two of these products to Phase 3 clinical trials, darapladib for cardiovascular disease and Syncria for type 2 diabetes mellitus. In addition, the company has a portfolio of drugs in earlier stages of development, led by TRAIL receptor antibody mapatumumab in mid-stage development for cancer.
BENLYSTA for systemic lupus and ZALBIN for chronic hepatitis C have met the primary efficacy endpoints of their pivotal Phase 3 trials.
BENLYSTA is a human monoclonal antibody that specifically recognizes and inhibits the biological activity of B-lymphocyte stimulator, or BLyS. BENLYSTA is being developed by the company and GSK as a potential treatment for systemic lupus under a co-development and commercialization agreement entered into in 2006.
ZALBIN (albinterferon alfa-2b)
ZALBIN (also known as JOULFERON) is a genetic fusion of human albumin and interferon alfa that was created using the companys proprietary albumin-fusion technology. ZALBIN is being developed by the company and Novartis for the treatment of chronic hepatitis C under a worldwide co-development and commercialization agreement. ZALBIN would be the brand name for albinterferon alfa-2b in the United States, and JOULFERON would be the brand name in the rest of the world. In January 2009, Novartis initiated a separate Phase 2b trial to explore various doses of ZALBIN administered monthly, in combination with ribavirin, in treatment-naïve patients with genotypes 2 and 3 chronic hepatitis C.
Raxibacumab is a human monoclonal antibody that specifically targets and blocks Bacillus anthracis protective antigen, which research has shown to be the facilitator of the deadly toxicity of anthrax infection. Raxibacumab represents a new way to address the anthrax threat.
The company develops agonistic antibody therapies for cancer based on the TRAIL receptor apoptotic pathway. Mapatumumab is a human monoclonal antibody that specifically binds to the TRAIL receptor 1 and causes it to induce apoptosis in cancer cells.
Non-small cell lung cancer: A randomized Phase 2 trial of mapatumumab in combination with paclitaxel and carboplatin as first-line therapy is ongoing in patients with advanced non-small cell lung cancer (NSCLC).
Multiple myeloma: A randomized Phase 2 trial of mapatumumab in combination with bortezomib (Velcade) is ongoing in patients with advanced multiple myeloma. Multiple myeloma is a cancer of the plasma cells in bone marrow.
Hepatocellular cancer: The safety lead-in to a randomized Phase 2 trial of mapatumumab in combination with Nexavar (sorafenib) is ongoing in patients with advanced hepatocellular cancer.
In November 2009, the company announced the initiation of a Phase 1 trial of IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors. The studys primary objectives include evaluation of safety and tolerability, and dose selection for Phase 2 trials. HGS1029 as monotherapy is also being studied in an ongoing Phase 1 study in patients with advanced solid tumors.
The company has co-development and commercialization agreements with pharmaceutical companies for both of its products GSK for BENLYSTA and Novartis for ZALBIN. Raxibacumab is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA) of the Office of the Assistant Secretary for Preparedness and Response (ASPR), U.S. Department of Health and Human Services (HHS).
In December 2010, Adimab, Inc. had a research collaboration with Human Genome Sciences Inc. The two companies have initiated a research program whereby Adimab would utilize its proprietary discovery platform to identify human antibodies against one target selected by Human Genome Sciences. The agreement gives Human Genome Sciences the option to commercialize antibodies generated from the collaboration.
Human Genome Sciences, Inc. was founded in 1992.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. HUMAN GENOME SCIENCES INC. COMPANY PROFILE
1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. HUMAN GENOME SCIENCES INC. BUSINESS OVERVIEW
2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. HUMAN GENOME SCIENCES INC. SWOT ANALYSIS
4. HUMAN GENOME SCIENCES INC. FINANCIAL ANALYSIS
4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. HUMAN GENOME SCIENCES INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. Human Genome Sciences Inc. Direct Competitors
5.2. Comparison of Human Genome Sciences Inc. and Direct Competitors Financial Ratios
5.3. Comparison of Human Genome Sciences Inc. and Direct Competitors Stock Charts
5.4. Human Genome Sciences Inc. Industry Analysis
5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
5.4.2. Human Genome Sciences Inc. Industry Position Analysis
6. HUMAN GENOME SCIENCES INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. HUMAN GENOME SCIENCES INC. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. HUMAN GENOME SCIENCES INC. ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. HUMAN GENOME SCIENCES INC. IFE, EFE, IE MATRICES2
10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. HUMAN GENOME SCIENCES INC. PORTER FIVE FORCES ANALYSIS2
12. HUMAN GENOME SCIENCES INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
Human Genome Sciences Inc. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
Human Genome Sciences Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
Human Genome Sciences Inc. Major Shareholders
Human Genome Sciences Inc. History
Human Genome Sciences Inc. Products
Revenues by Segment
Revenues by Region
Human Genome Sciences Inc. Offices and Representations
Human Genome Sciences Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
Human Genome Sciences Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
Human Genome Sciences Inc. Capital Market Snapshot
Human Genome Sciences Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Pharmaceuticals and Biotechnology Industry Statistics
Human Genome Sciences Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
Human Genome Sciences Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
Human Genome Sciences Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
Human Genome Sciences Inc. 1-year Stock Charts
Human Genome Sciences Inc. 5-year Stock Charts
Human Genome Sciences Inc. vs. Main Indexes 1-year Stock Chart
Human Genome Sciences Inc. vs. Direct Competitors 1-year Stock Charts
Human Genome Sciences Inc. Article Density Chart
1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
Enhanced SWOT Analysis
Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Upon answering these questions a company can develop a project plan to improve its business performance.
PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.
Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.
Key Factors Examined by PESTEL Analysis:
- Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
- Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
- Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
- Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
- Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.
The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.
The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.
Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.
Porter Five Forces Analysis
The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:
- Costly to imitate?
- Organized properly?